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Abstract
Oestrogens, trauma, infections or stress has been described as triggers for angioedema
(AE) attacks in patients with hereditary angioedema due to C1-inhibitor deficiency
(C1-INH-HAE). Microtrauma can precipitate the onset of acute AE attacks, and thus,
dental-oral procedures carry a high risk of triggering them and also an increased risk of
death from asphyxiation due to the AE location. In the past, without proper specific
treatment, the overall mortality after dental surgery in patients with C1-INH-HAE was
up to 30–40%. Some dental-oral, medical and/or surgical procedures are susceptible to
receive “short-term prophylaxis” (STP) in order to reduce the risk of AE. We describe the
published case reports of dental-oral, maxillofacial and ear, nose and throat (ENT)
procedures in patients with C1-INH-HAE. Different consensus algorithms and clinical
guidelines have been published for managing dental-oral, maxillofacial and otolaryngo-
logical procedures (DOMFOPs) and will be reviewed below. Based on the clinical
experience of the Department of Allergology of the University Hospital La Paz (Madrid)
and the University General Hospital Nuestra Señora del Prado (Talavera de la Reina),
these algorithms have been updated and modified. We advise to classify procedures
according to the risk of producing AE as minor, intermediate and major risks.
Keywords: algorithm, angioedema, antifibrinolytic agents, attenuated androgens, bra-
dykinin, C1 inhibitor, dental-oral procedures, dental surgery, ecallantide, hereditary
angioedema, icatibant acetate, recombinant human C1 inhibitor, plasma-derived human
C1-inhibitor concentrate, short-term prophylaxis, solvent/detergent-treated plasma,
treatment
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1. Introduction
Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) is a genetic autosomal
dominant disease characterized by a deficiency of the functionally active C1 esterase inhibitor
(C1-INH) protein [1]. This deficiency results in an excess of bradykinin (BK), which increases
vascular permeability and produces angioedema (AE) [1].
The minimum prevalence of C1-INH-HAE is 1.09 per 100,000 inhabitants in Spain [2], 1.41 per
100,000 inhabitants in Denmark [3], 1.54 per 100,000 inhabitants in Italy [4] and 1.75 per 100,000
inhabitants in Norway [5].
Other forms of BK-mediated AE are: acquired angioedema due to C1-INH deficiency (C1-INH-
AAE), hereditary angioedema with normal C1-INH (C1-INH-nC1-INH), with/without muta-
tion in the F12 gene that encodes Factor XII coagulation (HAE-FXII/HAE-D) and acquired
angioedema associated with angiotensin converting enzyme inhibitors (ACEi) (AAE-ACEi).
ACEis are drugs that inhibit the metabolic pathways of BK and thus produce an increase in BK.
Other drugs that inhibit BK catabolism have been implicated in the development of AE. These
include dipeptidyl peptidase IV (DPPIV) inhibitors, aminopeptidase P (APP) inhibitors, neu-
tral endopeptidase (NEP) inhibitors and others. In this chapter, we will focus on C1-INH-HAE.
2. The importance of cervicofacial anatomical location in C1-INH-HAE
angioedema attacks
Oestrogens, trauma, infections or stress has been described as triggers for AE attacks in 21
patients with C1-INH-HAE [6]. Microtrauma can precipitate the onset of acute AE attacks, and
thus, dental-oral procedures carry a high risk of triggering them and also an increased risk of
death from asphyxiation due to the AE location [7]. Treatment with adrenaline, antihistamines
or glucocorticoids is not effective in this type of BK-mediated AE [8].
In the past, without proper specific treatment, overall mortality after dental surgery in patients
with C1-INH-HAE was up to 30–40% [9–12]. Some dental-oral, medical and/or surgical pro-
cedures are susceptible to receive “short-term prophylaxis” (STP) (also called “pre-procedural
prophylaxis”) [8, 13–15] in order to reduce the risk of AE. Such prophylaxis in patients with
C1-INH-HAE usually consists of introducing oral antifibrinolytics or attenuated androgens
(AAs) or administering intravenous pdhC1INH before the procedure [8, 13]. There are cur-
rently two brands of pdhC1INH available: Berinert® (CSL-Behring, Marburg, Germany) and
Cinryze® (Shire-HGT, Zug, Switzerland). Since upper airway AE can cause death from
asphyxiation [13, 16], adequate monitoring of upper airway permeability is imperative, so that
appropriate emergency treatment (endotracheal intubation and/or tracheotomy) is performed
if the upper airway is threatened despite medical treatment [8, 17]. Nevertheless, the availabil-
ity of specific drugs for the treatment of acute AE attacks and of plasma-derived human
C1-inhibitor concentrates (pdhC1INH) (Berinert®, CSL Behring, Marburg, Germany and
Cinryze®, Shire HGT, Zug, Switzerland) for STP, together with the increased awareness of
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pre-procedural prophylaxis, has reduced the prevalence of upper airway respiratory AE and
death from asphyxiation after dental procedures [15, 18].
3. Management of dental-oral, maxillofacial and ENT procedures
(DOMFOPs) in patients with C1-INH-HAE
A review of published case reports of dental-oral, maxillofacial and ear, nose and throat (ENT)
procedures in patients with C1-INH-HAE is shown in Table 1.
Case report (gender/age) STP AE type AE
development
Reference
pdhC1INH FFP Icatibant
acetate
One male and five females aged
between 18 and 64 y.o.
N.AD 2 Units N.AD C1-INH-HAE
type I
None Jaffe et al. [19]
Three males aged between 41 and
56 y.o.
N.AD N.AD N.AD C1-INH-HAE None Heft and
Flynn [20]
One female of 28 y.o. N.AD N.AD N.AD C1-INH-HAE None
One female of 45 y.o. N.AD 1 Unit N.AD C1-INH-HAE
type I
None Delfino et al.
[21]
One female of 22 y.o. N.AD 2 Units N.AD C1-INH-HAE
type I
None Allbright and
Taylor [22]
One male of 20 y.o. N.AD N.AD N.AD C1-INH-HAE None Sturdy et al.
[23]
One female of 32 y.o. N.AD 2 Units N.AD C1-INH-HAE
type I
None Mauro et al.
[24]
One male of 37 y.o. N.AD 2 Units N.AD Unknown None Malmstrom
et al. [25]
One female of 40 y.o. N.AD 4 Units N.AD C1-INH-AAE
type II
Laryngeal
oedema
Degroote
et al. [26]
One male of 32 y.o. N.AD 6 Units N.AD C1-INH-HAE
type I
None Phillips et al.
[27]
One female of 18 y.o. 2000 IU N.AD N.AD C1-INH-HAE
type I
None Leimgruber
et al. [28]
N.AD N.AD N.AD Laryngeal
oedema
One male and two females aged
between 34 and 49 y.o.
N.AD 4 Units N.AD C1-INH-HAE
type I
None Peled et al.
[29]
N.AD 4 Units N.AD C1-INH-HAE
type I
None
One female of 10 y.o. N.AD 2 Units N.AD C1-INH-HAE
type I
None Karlis et al.
[30]
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Case report (gender/age) STP AE type AE
development
Reference
pdhC1INH FFP Icatibant
acetate
Six males and six females aged
between 21 and 50 y.o.
N.AD N.AD N.AD C1-INH-HAE
type I
None Farkas et al.
[31]
One male of 4 y.o. N.AD Used N.AD Unknown None Webb et al.
[32]
One female of 6 y.o. N.AD N.AD N.AD HAE None
One female of 54 y.o. 500 IU N.AD N.AD C1-INH-HAE
type I
None Maeda et al.
[33]
Three females aged between of 27
and 32 y.o.
N.AD N.AD N.AD C1-INH-HAE
type I
Laryngeal
oedema
Börk and
Barnstedt [18]
One male of 46 y.o. N.AD N.AD N.AD C1-INH-HAE
type I
Laryngeal
oedema
One female of 28 y.o. N.AD N.AD N.AD C1-INH-HAE
type I
Laryngeal
oedema
Rice et al. [34]
One female of 49 y.o. N.AD N.AD N.AD C1-INH-HAE
type I þ AAE-
ACEi
Laryngeal
oedema
Van Sickels
et al. [35]
One female of 33 y.o. N.AD N.AD N.AD C1-INH-HAE
type I
None
(danazol)
One female of 8 y.o. Used N.AD N.AD C1-INH-HAE None
(danazol)
Moraes et al.
[36]
One male of 36 y.o. N.AD N.AD N.AD C1-INH-HAE
type II
Laryngeal
oedema
Baccioglu
Kavut [37]
1000 IU N.AD N.AD None
One female of 28 y.o. N.AD N.AD SC 30 mg C1-INH-HAE
type I
None Senaratne
et al. [38]
One female of 45 y.o. N.AD N.AD SC 30 mg C1-INH-HAE None Angeletti
et al. [39]
One female of 6 y.o. 500 IU N.AD N.AD C1-INH-HAE
type II
None Narayanan
et al. [40]
Two males aged between 19 and
57 y.o. and one female of 20 y.o.
N.AD N.AD N.AD C1-INH-HAE
type I
Minimal
pharyngeal
oedema
Jurado-
Palomo et al.
[15]
One female of 26 y.o. 1000 IU N.AD N.AD C1-INH-HAE
type I
None Sanuki et al.
[41]
One female of 50 y.o. N.AD N.AD N.AD C1-INH-HAE Laryngeal
oedema
Forrest et al.
[42]
FFP = fresh frozen plasma, IU = International Unit, N.AD = not administered, pdhC1INH = plasma-derived human C1
esterase inhibitor, SC = subcutaneous, STP = short-term prophylaxis and y.o. = years old.
Table 1. Literature review of dental-oral, maxillofacial and ENT procedures in patients with C1-INH-HAE.
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4. The development of diagnostic-therapeutic algorithms for dental-oral,
maxillofacial and otolaryngological procedures (DOMFOPs) according to
the risk of triggering angioedema attacks
In the last 12 years, different consensus algorithms and clinical guidelines have been published
for managing DOMFOP STP and will be reviewed below.
4.1. The 2003 Hungarian-Canadian consensus algorithm
The 2003 Hungarian-Canadian consensus was the first consensus document on the manage-
ment of C1-INH-HAE [43]. It attempted to establish a separation between minor and major
DOMFOPs but did not go deeper in differentiating clearly which procedures were considered
minor or major (Figure 1) [43].
According to the 2003 Hungarian-Canadian consensus, the STP in DOMFOPs should be as
follows:
1. If only a minimum dental manipulation was going to be performed and pdhC1INH was
available for the treatment of acute AE attacks, no pre-procedural prophylaxis was indi-
cated. However, if pdhC1INH was not available, STP with danazol or tranexamic acid
was recommended. Local injection of local anaesthetic was recognized as being able to
precipitate an AE attack [43].
2. For a manipulation that was not considered minor, danazol was recommended (even in
children and pregnant women in the last trimester). Tranexamic acid was considered as an
Figure 1. Short-term prophylaxis algorithm for C1-inhibitor deficiency according to the 2003 Hungarian-Canadian
consensus [43].
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alternative to danazol. pdhC1INH should be available for immediate administration if an
AE attack developed [43]. In case of a major surgical procedure or if the patient was being
intubated, intravenous pdhC1INH had to be administered 1 hour before surgery. A
second pdhC1INH dose should be administered during surgery and even repeated daily
or as much as needed until there was no risk of developing AE. If pdhC1INH was not
available, STP with danazol or tranexamic acid was recommended. Solvent/detergent-
treated fresh frozen plasma (SD-FFP) 1 or more hours before procedure could be another
alternative if pdhC1INH was not available; regular FFP would be a fourth option,
although less safe than SD-FFP [43].
The algorithm summarizing the recommendations for surgical risk of the Hungarian-Cana-
dian consensus 2003 can be seen in Figure 1 [43].
4.2. The 2005 British consensus algorithm
According to the 2005 British consensus [16], STP was not only indicated before risky pro-
cedures or surgeries but also during periods of physiological or psychological stress (also
called intermittent long-term prophylaxis). It was the first time that the term “intermittent
long-term prophylaxis” was used. The proposed STP scheme was as follows:
• pdhC1INH (500–1500 U, generally 1000 U) up to 24 hours before. Additional doses may
be required later, basically if postoperative infection occurs. It was the treatment of choice
in major dental procedures such as tooth extractions.
• Tranexamic acid from 2 to 5 days before procedure until 2 days after procedure
– 4 g/day (1 g 4 times/day)
• Attenuated androgens from 2 to 5 days before procedure to 2 days after procedure
– Danazol: 100–600 mg/day
– Stanozolol: 2–6 mg/day
4.3. The 2007 Hungarian-Canadian consensus algorithm
The 2007 Hungarian-Canadian consensus (published in 2008) continued the distinction between
minor or major procedures and intubation (Figure 2) [44].
Unlike the 2003 Hungarian-Canadian algorithm, the recommendation of the use of tranexamic
acid in minor manipulations with available pdhC1INH was removed. In addition, in major
procedures or intubation, the recommendation of the use of danazol or tranexamic acid was
also removed, and recommendations differed according to the availability or non-availability
of pdhC1INH.
4.4. The 2010 international consensus algorithm
The International consensus published in Allergy, Asthma and Clinical Immunology (official
publication of the Canadian Society of Allergy and Clinical Immunology) in 2010 updated the
STP recommendations (Figure 3) [13].
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A distinctive feature is that the time period for STP with oral drugs for minor risk procedures
was increased from 5 days before the procedure to 2–5 days after the completion of the
procedure [13]. It also emphasizes the non-use of danazol during the first two trimesters of
pregnancy because of the obvious risks of AAs. Antifibrinolytics are still not recommended for
STP in this type of procedures.
In procedures involving a higher AE risk or endotracheal intubation, pdhC1INH should be
administered from 1 to 6 hours before the procedure, if available. As in previous consensus
documents, it only distinguishes between DOMFOPs of minor or major risk, not considering
“intermediate risk”.
Figure 2. Prophylaxis algorithm in C1-inhibitor deficiency of the 2007 Hungarian-Canadian consensus [44].
Figure 3. Prophylaxis algorithm in C1-inhibitor deficiency in the 2010 international consensus [44].
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4.5. The 2011 Spanish consensus algorithm
According to the Spanish consensus [8], STP was indicated in surgery or medical procedures
that involve trauma in the cervicofacial region with the risk of laryngeal oedema development
(e.g. dental manipulations, tonsillectomy, maxillofacial surgery, endoscopy, bronchoscopy or
interventions requiring endotracheal intubation) and to prevent local oedema that could alter
the surgeon's work area and may affect the surgical outcome.
Specific acute treatment (pdhC1INH or icatibant acetate) must be available with appropriate
monitoring of the patient after surgery, including an action plan.
The recommendations were as follows:
• Intravenous pdhC1INH (500 U if the patient weighs less than 50 kg and 1000 U if he/she
weighs more than 50 kg) administered from 1 to 4 hours prior to the procedure, with a
required second dose (if available).
• Intravenous SD-FFP (if pdhC1INH is not available), two units administered 1 hour before
the procedure.
• AAs from 5 to 7 days before to 2–3 days after the procedure (in case of postoperative
complications such as infections, AAs should be continued for more than 5 days.)
– Danazol: 400–600 mg/day
– Stanozolol: 4–6 mg/day
• Antifibrinolytics
– EACA
– Tranexamic acid: 1–4 g/day or 75 mg/kg/day divided into 2–3 doses from 5 days before
to 2 days after surgery
Drugs and doses for STP are summarized in Table 2.
Pharmacological
group
Drug Adults Children
C1-INH replacement pdhC1INH 500–1500 U, 1–4 hours before event 20 U/kg, 1 hour before event
FFP 2 U (400 ml), 1 hour before procedure 10 mL/kg 1 hour before procedure
Attenuated
androgens
Danazol 400–600 mg/24 hours for 5–7 days before and
2–3 days post-event
10 mg/kg/day for 5–7 days before to
2–3 days post-event
Stanozolol 4–6 mg/24 hours for 5 days before and 3 days
post-event
Antifibrinolytics
(seldom used)
Tranexamic
acid
1 g/6 hours for 5 days before and 2 days
post-event
500 mg/6 hours for 2 days before and
2 days post-event
Table 2. Short-term prophylaxis in the Spanish 2011 national consensus on C1-INH-HAE.
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4.6. The 2012 management guidelines of the World Allergy Organization (WAO)
This was the first guideline on C1-INH-HAE and thus was the first time in which evidence
levels were analysed and graded recommendations were given [45].
There was no evidence about the effectiveness of STP. The advice to administer STP was based
on Expert Opinion. It was stated that even though STP was used, AE episodes could still occur
and sometimes after minor procedures (case reports, series of patients). Nevertheless, several
publications had reported a reduction in the incidence of AE with STP in both adults and
children. In this guideline, the indications of STP varied according to:
• The patient's personal history: frequent episodes of AE, AE following a similar procedure
(dental or oral surgery), need for intubation, more invasive procedures
• Probability of AE associated with such a procedure
• Periods of high risk of attacks (due to increased likelihood of AE attacks or increased
consequences of AE attack): periods of stress, tests
STP administration had to be considered prior to surgery, especially in the case of dental/
intraoral procedures, in which endotracheal intubation was required, when the airway or
pharynx was manipulated and before bronchoscopy or endoscopy. This statement had a level
of evidence D (adapted from previous consensus document or “statement” based on an expert
opinion poll during a consensus conference) and a strength of recommendation A.
In DOMFOPs with minimal risk or if there was availability of safe drugs for on-demand
treatment of “upper airway edema” (UAE) attacks, STP could be omitted. Two doses of
pdhC1INH, ecallantide or icatibant had to be available for possible immediate administration.
The patient had to know the risks and have a plan of action and treatment for AE attacks.
The recommendations were as follows:
• Intravenous pdhC1INH: 10–20 U/kg or 1000 U was recommended, administered from 1 to
6 hours before DOMFOP. Dosing studies were required, as AE attacks have even occurred
with 1000 U doses
• SD-FFP (if pdhC1INH was not available)
• AAs from 5 days before to 5 days after the procedure (if the risk associated with the
procedure or surgery was relatively low and no pdhC1INH was available). Its use was
limited to elective surgery with a lower perceived effectiveness as compared to pdhC1INH,
although there was no evidence. AAs have considerable side effects, being contraindicated
during pregnancy (except in the last trimester of pregnancy) and during lactation
– Danazol: 2.5–10 mg/kg/day, to a maximum dose of 600 mg/day
– Stanozolol: 4–6 mg/day
• Antifibrinolytics
– Tranexamic acid: 25 mg/kg/day divided into 2–3 doses
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4.7. The 2013 guidelines for the management of HAE, C1-INH-AAE and ACEi-AAE
All HAE patients are candidates for STP when exposed to situations that could likely trigger
an AE attack [46].
Two statements are particularly relevant in this field:
1. Summary statement 20: STP can be achieved by using FFP, pdhC1INH and high doses of
AAs for short periods. Recommendation strength B (directly based on category II evi-
dence or recommendation extrapolated from category I evidence).
2. Summary statement 25: New drugs for the treatment of C1-INH deficiency syndromes are
costlier than the alternative treatment with AAs. Official studies of cost-utility and cost-
effectiveness in helping healthcare providers in the management of patients with C1-INH
deficiency syndromes are warranted. Strength of recommendation D.
The drugs and doses recommended are as follows:
• Intravenous pdhC1INH: 1000–2000 U
• Intravenous SD-FFP 2 U: several hours (up to 12 hours) before the procedure
• Oral 17-alpha-alkylated AAs, for 5–10 days before to 2 days after the procedure
– Danazol: 6–10 mg/kg/day into divided doses; maximum 200 mg, 3 times per day or
equivalent
There are no comparative studies between pdhC1INH and AAs. The decision on the drug to
be prescribed should be based on an individualized assessment of damage/burden compared
to the benefits, costs and patient preferences. In emergency procedures, pdhC1INH is the
treatment of choice. Specific treatment for AE attacks (pdhC1INH, ecallantide or icatibant)
should be available during and after any procedure.
4.8. The 2014 Canadian consensus
STP should be considered prior to the patient's specific known triggers and before any medical,
surgical or dental procedures [47]. Evidence level is low, and the strength of the recommendation
is strong.
Specific treatments for the acute attack of C1-INH-HAE should be available during and after
the procedure. The level of evidence is low (our confidence in the estimated effect is limited:
the true effect may be substantially different from the estimated effect). The strength of the
recommendation is strong.
The drugs and doses recommended were as follows:
• pdhC1INH: pdhC1INH was recommended, although there were no data on the most
appropriate dose. In Europe, it was marketed under the following brands:
– Cinryze®: 1000 U up to 24 hours before, though there is not enough evidence that
confirms that administering the drug more than 6 hours before the procedure is safe
– Berinert®: 1000 U up to 6 hours before
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• AAs from 5 days before to 2–3 days after the procedure (STP could be considered when
the risk associated with surgery was low and there was no immediate availability of the
specific treatments for acute attacks)
– Danazol: 2.5–10 mg/kg/day, up to a maximum dose of 600 mg/day
• Antifibrinolytics
– Tranexamic acid: 25 mg/kg/day (up to a maximum dose of 3000–6000 mg/day) divided
into 2–3 doses from 5 days before to 2–5 days after the surgery or when a trigger was
anticipated. Its effectiveness in preventing attacks was unknown, so it should only be
used if other drugs were not available
4.9. The 2013 Spanish algorithm for short-term prophylaxis
A group of allergists along with clinical pharmacologists from different hospitals in Spain
developed algorithms for the diagnosis, prophylaxis and treatment of C1-INH-HAE [48].
STP was not indicated in minor procedures with the availability of specific treatment for acute
AE attacks. STP was indicated in all the procedures that involved trauma in the cervicofacial
region because of the risk of developing AE in the upper airway and in any diagnostic or
therapeutic procedure in order to avoid local edema in the working area so that the procedure
result was not altered.
pdhC1INH was the election treatment for STP. Both Cinryze® 1000 U (1–24 horas pre-
procedure) and Berinert® 10–20 U/kg (1–6 hours of pre-procedure) were available for their 20
use in adults.
In case pdhC1INH was not available, attenuated androgens (danazol, estanozolol) and
antifibrinolytics (tranexamic acid, epsilon aminocaproic acid) were alternatives in
programmed procedures and SD-FFP in case of emergency procedures.
• Danazol: 400–600 mg/day (divided into 2–3 doses/day—from 5 to 7 days pre-procedure to
2–3 days post-procedure)
• Stanozolol: 4–6 mg/day (divided into 2–3 doses/day—from 5 to 7 days pre-procedure to 3
days post-procedure)
• Tranexamic acid: 1,000 mg/6 hours (from 5 days pre-procedure to 2–3 days post-proce-
dure (consider thrombotic risk)
It was advised that any patient receiving STP should be observed and the specific treatment for
acute attacks should be available for 48 hours after the procedure, as the risk for AE is not
totally cancelled with STP.
These authors specified STP for children. The election treatment was also intravenous—
pdhC1INH (Berinert®: 10–20 U/kg, 1–6 hours pre-procedure or Cinryze® 1000 U).
In case pdhC1INH was not available, they advised to use attenuated androgens or tranexamic
acid:
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• Danazol: 10 mg/kg/day (divided into 2–3 doses/day—from 5 to 7 days pre-procedure to
2–3 days post-procedure)
• Tranexamic acid: 500 mg/6 hours (from 5 days pre-procedure to 2–3 days post-procedure)
4.10. International consensus for the management of children with C1-INH-HAE
According to the international consensus for the management of children [49] (Figure 4),
indications for STP in paediatrics (as in adults) include patient-specific triggers, medical and
dental procedures. For most “minor interventions”, the recommendation is to choose an on-
demand treatment if a swelling event is precipitated rather than prophylaxis, provided that a
licensed on-demand medication is immediately available in the case of emergency (level III
evidence).
4.11. US consensus for the management of children with C1-INH-HAE
Only Berinert® is approved for the treatment of children < 12 y.o. [50]. Berinert®, at 20 U/kg,
has less risk of containing an infectious agent, is approved by the Food and Drug Administra-
tion (FDA) in children and is preferable when available [51–53].
FFP given empirically at 2 U per patient immediately before surgery has been reported to
provide effective STP in adults and poses less risk [19]. It is critically important that effective
on-demand treatment be available, whether the patient is given STP prophylaxis or not.
Therapeutic approaches for C1-INH-HAE have been studied carefully in adults, but not all
have not been investigated with the same level of care in children (Table 3).
Figure 4. Prophylaxis algorithm in C1-inhibitor deficiency in the 2017 international consensus for the management of
children [49].
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4.12. Available treatments for STP in C1-INH-HAE
4.12.1. Plasma-derived C1 esterase inhibitor concentrate (pdhC1INH)
pdhC1INH consists of a replacement therapy for the lacking C1-INH. There are currently
several pdhC1INH pharmaceutical presentations: Berinert® (CSL-Behring GmbH, Marburg,
Germany), Cebitor® (Sanquin, Amsterdam, The Netherlands) and Cinryze® (Shire HGT, Zug,
Switzerland) (see Table 4 for a comparison of the available drugs for short-term prophylaxis in
C1-INH-HAE).
For nearly 25 years, Berinert-P (CSL-Behring GmbH) was available in Spain through the
Foreign Medications office [8]. Afterwards, it was finally marketed in Spain as Berinert® in
August 2009 [8]. Berinert® is a purified, pasteurized, nanofiltred pdhC1INH. It is presented in
500 U vials of a lyophilized product for intravenous administration, which has to be stored at
2–25C [8], and when reconstituted, a 50 IU/mL solution is formed. It has an excellent safety
post-launch record after more than 35 years of its availability [54–56].
Berinert® is currently approved by the FDA for the treatment of AE attacks in adults and
adolescents, 12 years and older, with C1-INH-HAE, and by the European Medical Agencies
(EMA) for the treatment of AE attacks and short-term prophylaxis in adults and children with
C1-INH-HAE [56].
Cebitor® is only available in a few European countries.
Cinryze® comes in a package with two lyophilized 500 U C1 inhibitor (human) vials. After
reconstitution, each vial contains a 100 U/ml solution. It has to be stored from 2 to 25C.
The FDA approved Cinryze in October 2008 for long-term prophylaxis in adults (> 18 years)
[8]. In 2010, the European Medicines Agency (EMA) approved the marketing of Cinryze® for
long-term prophylaxis, short-term-prophylaxis and the treatment of acute attacks in adoles-
cents and adults [57].
Drugs Type of evidence Dosage Use
Berinert® I (adults) and II-3 (children) 20 IU/kg intravenous On demand
Cinryze® I (adults >18 y.o.) and II-3 (children) 1000 IU intravenous (adults) Prophylaxis
Ruconest® I (adults ≥ 18 y.o.) 50 IU/kg intravenous On demand
Icatibant acetate I (adults ≥ 18 y.o.) and II-3 (children) 30 mg subcutaneous On demand
Ecallantide I (adults, adolescents ≥ 12 y.o.) and II-3 (children) 30 mg subcutaneous On demand
Danazol I (adults) and II-3 (children, not recommended) <200 mg oral Prophylaxis
Tranexamic acid II-3 (adults and children) 20–40 mg/kg up to 3 g/day oral Prophylaxis
Fresh frozen plasma II-3 (adults) 1–2 Units intravenous On demand
Type of evidence I = randomized controlled trial and II-3 = dramatic results in uncontrolled trial.
Table 3. Drugs for prophylaxis and for the acute treatment of hereditary angioedema (modified Frank et al.) [50].
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Drug Trade name Company Drug
description
Mechanism of
action
Administration
route
Indication for STP Adverse events
Human
plasma-
derived C1-
INH
Berinert® CSL-Behring Human
plasma-derived
C1-esterase
inhibitor
C1-INH
replacement1
Intravenous - Adults: 1000 IU, 1–6
hours before procedure
- Children: 15–30 IU/kg 1–6
hours before procedure
Rare: risk of anaphylaxis,
thrombosis
Theoretical: transmission of
infectious agent
Human
plasma-
derived C1-
INH
Cebitor®,
Cinryze®
Sanquin, Shire
HGT
Human
plasma-derived
C1-esterase
inhibitor
C1-INH
replacement
Intravenous 1000 U, 1–24 hours before
procedure2
Conestat-alfa
(recombinant
human C1-
INH produced
in transgenic
rabbits)
Rhucin®/
Ruconest®3
Pharming NV Recombinant
human
inhibitor of C1-
esterase
(produced in
transgenic
rabbits)
C1-INH
replacement
Intravenous No Rare: risk of anaphylaxis
(screening for IgE antibodies
against rabbit dander is
advised by EMA)
Icatibant
acetate
Firazyr® Shire HGT Synthetic
peptide (10 aa)
Blockage of B2R Subcutaneous No Common: local swelling, pain
and pruritus at injection site
Attack can recur in the
following 48 hours
Theoretical: worsening of an
ongoing acute coronary artery
disease
Ecallantide Kalbitor® Shire HGT Recombinant
human protein
(60 aa)
Selective inhibitor
of plasma
kallikrein
Subcutaneous No Common: prolonged PTT
Uncommon: risk of
anaphylaxis (must be
administered by healthcare
professionals)
Solvent/
detergent-
treated plasma
(SD-FFP)
Several Plasma
derivative
Replacement of
deficient C1-INH
protein
Intravenous Adults: 2–4 U
Children: 10 mL/kg
1–6 hours before
procedure4
Transmission of infectious
agents: only S/D treatment
inactivates enveloped viruses
but not non-enveloped ones
Risk of hypervolaemia: large
volumes can overload the
circulatory system
Allergenic potential: large
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Drug Trade name Company Drug
description
Mechanism of
action
Administration
route
Indication for STP Adverse events
number of potentially
allergenic constituents
Epsilon-amino-
caproic acid
(EACA)
Caproamin®,
Amicar®
Rottapharm,
Xanodyne
Pharmaceuticals
Antifibrinolytic:
antiplasmin and
plasminogen
activator inhibitor
effect
Oral,
intravenous
Common: nausea, vertigo,
diarrhoea, postural
hypotension, fatigue, muscle
cramps with increased muscle
enzymes
Uncommon: thrombosis
Tranexamic
acid
Amchafibrin®,
Cyklokapron®
Pfizer, New
York, NY
Cyclic
derivative of
epsilon amino-
caproic acid
Oral,
intravenous
500–3000 mg/day divided
into 3–4 doses
Adults: 1 g/6h
Children: 500 mg/6h
2 days pre-procedure and 2
days post-procedure
Stanozolol Winstrol® Winthrop,
Barcelona,
Spain
Attenuated
androgen (17-
alpha-alkylated
androgens)
Increase in plasma
C1-esterase
inhibitor levels
Oral 2 mg/day or less
4–6 mg/day (divided into
2–3 doses), 5 days pre-
procedure and 3–5 days
post-procedure
Common: weight gain,
virilization, acne, altered
libido, muscle pain, headaches,
depression, fatigue, nausea,
constipation, menstrual
abnormalities, increase in liver
enzymes, hypertension,
alterations in lipid profile
Uncommon: decreased growth
rate in children,
masculinization of female
foetus, cholestatic jaundice,
peliosis hepatis, hepatocellular
adenoma
Danazol Danatrol,
Danocrine,
Danol
Sanofi-Aventis,
Paris, France
Attenuated
androgen (17-
alpha-alkylated
androgen)
Increase in plasma
C1-esterase
inhibitor levels;
increase in plasma
aminopeptidase P
levels
Oral 200 mg/day or less, 5 days
pre-procedure and 3–5
days post-procedure
Adults: 400–600 mg/day
(divided into 2–3 doses)
Children: 10 mg/kg/day
(divided into 2–3 doses)
Oxandrolone Oxandrin® Savient
Pharmaceu
ticals, East
Brunswick, NJ
Attenuated
androgen (17-
alpha-alkylated
androgen)
Increase in plasma
C1-esterase
inhibitor levels
Oral 10 mg/day or less
1 Inhibits plasma kallikrein, factors XIIa and XIa, C1s, C1r, plasmin.
2 Cinryze® SPC (Summary of Products Characteristics) indicates 1–24 hours, but the authors consider it should be administered as close as possible to the procedure and no
longer than 6 hours prior to procedure.
3 Conestat alfa is commercialized as Ruconest® in Europe and Rhucin® in other parts of the world.
4 As close to procedure as possible.
Table 4. Drugs for the treatment of C1-INH-HAE with special focus on STP.
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Both Berinert® and Cinryze® are currently authorized for intravenous self-administration by
trained patients or their relatives.
The recommended doses for STP are 1000 U for adults both for Berinert® and Cinryze® and
15–30 IU/kg for children for Berinert®, 1–6 hours before procedure. Although the Cinryze®
Summary of Products Characteristics (SPC) indicates 1–24 hours, most authors consider that it
should be administered as close as possible to the procedure and no longer than 6 hours prior
to procedure [58]. For long, complex surgeries and in the case of infection or other trigger
factors, the pdhC1INH dose may have to be repeated.
At least one dose of a specific drug for the treatment of acute AE attacks (C1-INH concentrate,
rhC1INH, ecallantide or icatibant) should be available for on-demand treatment in case it is needed.
4.12.2. Fresh frozen plasma
In countries where pdhC1INH is not available, fresh frozen plasma (FFP) is an alternative. FFP
should be virally inactivated with solvents and detergents (SD-FFP) to be safer. FFP acts by
supplying lacking C1-INH [8]. SD-FFP dosage for C1-INH-HAE has not been studied, and the
generally used dose is the same than in coagulation disorders: 2 units of 200 mL each [8].
Among the possible FFP side effects are alloimmunization, anaphylactic or allergic reactions,
transmission of infectious diseases (viruses, Creutzfeldt-Jakob disease) and excessive intravas-
cular volume with the risk of hypervolemia and heart failure [8].
4.12.3. Attenuated androgens
Danazol and stanozolol are 17-α-alkylated synthetic derivatives, which are very effective and
have fewer side effects than other androgens. Their mechanism of action in C1-INH-HAE is not
well known. Several actions may contribute to their effectiveness. First, a significant increase in
C1-INH plasma levels was reported with high AA doses. Second, an increase in the expression of
C1-INH mRNA in mononuclear cells with the minimum effective dose was shown. Finally, an
increase in the plasma levels of aminopeptidase P, one of the BK catabolizing enzymes, was
published [8].
Danazol is a potent gonadotropic inhibitor with partial antigestagenic, anabolic and androgenic
activity, whereas stanozolol is an anabolic steroid with certain anticoagulant properties [8].
Oxandrolone is another AA, which has been used in C1-INH-HAE to a lesser extent [8].
AAs have considerable side effects when used as long-term prophylaxis for long periods of
time or at high doses [8]. The main secondary effects are disorders of libido, impotence, weight
gain, menstrual irregularities, breast atrophy/hypotrophy, acne, voice changes, increased ath-
erogenic index, polycythemia, hypertension, haematuria, transient increases in transaminases,
hepatic necrosis, cholestatic hepatitis, hepatosplenic peliosis, transient increases in muscle
enzymes (creatine phosphokinase and aldolase) and rhabdomyolysis. There have also been
some cases of hepatic adenoma and adenocarcinoma. However, the data on increased risk of
atherosclerosis are controversial. AAs used for short periods of time as STP are much better
tolerated, and thus, they were advised as STP for children and pregnant women in the first
consensus documents on C1-INH-HAE.
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The effect of AAs takes approximately 5 days, and thus, AAs cannot be used in emergency
situations that require STP. AA doses for STP can be seen in Table 3.
These drugs may have to be administered for more than 5 days after the procedure in the case
of postoperative complications, especially infection [8].
4.12.4. Antifibrinolytic agents
The mechanism of action of antifibrinolytic agents in C1-INH-HAE is unknown.
4.12.4.1. ε-Aminocaproic acid
ε-Aminocaproic acid (EACA) (Amycar®, Rottapharm Madaus, Milan, Italy) is effective in
preventing AE attacks in C1-INH-HAE if taken as long-term prophylaxis [8, 14]. There is a scarcity
of data about its use as STP, although some consensus documents advise on its use [13, 44].
The most frequent side effect is a transient increase in creatine phosphokinase and aldolase
associated with muscle pain, weakness and fatigue. Other side effects are thrombosis and
extensive muscle necrosis [8].
4.12.4.2. Tranexamic acid
Tranexamic acid (Amchafibrin®, Rottapharm Madaus, Milan, Italy) is a cyclic derivative of
EACA and has been proven efficacious in preventing AE attacks in patients with C1-INH-HAE
[8, 14]. Tranexamic acid competitively inhibits the activation of plasminogen, which, under
normal conditions, is inhibited by C1-INH, thus reducing the conversion of plasminogen to
plasmin (fibrinolysis) [8].
Muscle cramps, nausea, diarrhoea, hypotension, dizziness and fatigue are among its described
side effects.
The dose for STP is 1 g 4 times a day or 75 mg/kg/day divided into 2–3 doses from 5 days
before to 2 days after the surgery or medical procedure.
Antifibrinolytics are seldom used in countries where other treatments are available. Antifibri-
nolytics should be discontinued before the surgery, as they may theoretically promote throm-
boembolic events [8].
4.12.5. Icatibant acetate
Icatibant acetate (Firazyr®, Shire HGT, Zug, Switzerland) is a synthetic decapeptide similar to
BK and a highly specific, potent and competitive antagonist of the BK B2 receptor (B2R),
inhibiting the vasodilation produced by BK [8]. Its effectiveness as the treatment for AE acute
attacks in C1-INH-HAE has been shown in clinical trials and patient series [8] and in patient
registries [59–61]. No serious adverse reactions have been reported, the only significant side
effect being injection site reactions (in more than 95% of cases), consisting of self-limiting
erythema, oedema, pruritus and pain [8]. The European Medicines Agency (EMA) approved
icatibant acetate for the treatment of acute AE attacks in adult patients (≥ 18 y.o.) with C1-INH-
HAE in July 2008, and it has been available in Spain since March 2009. It was approved by the
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FDA in 2011. Icatibant acetate's self-administration was authorized by EMA in 2011. A registry
on the use of icatibant acetate in real life has confirmed its safety [61].
Icatibant acetate is only approved for adults. A study on its safety and efficacy in children is
currently going on. There is no information about its safety profile in women who are preg-
nant. Regarding breastfeeding, lactation should be avoided 12 hours after icatibant acetate's
administration. According to prescribing information, icatibant acetate should not be used in
patients with active ischemic heart disease or those who have had an ischemic stroke in the
preceding 2 weeks [8].
Isolated cases of STP with off-label icatibant acetate prior to some medical, dental or surgical
procedures in patients with C1-INH-HAE have been published [38, 62, 63]. First, a thyroid
biopsy without later local oedema was published [62].
However, controlled studies are necessary. The short half-life (1–2 hours) of this agent and the
fact that it blocks B2R but does not diminish the BK production may restrict its use in short-
term prophylaxis, as there is a theoretical risk of late local oedema. The trauma may result in
an increase in local BK through FXII activation. While B2R blockage continues, no oedema is
produced, but when B2Rs are released (after icatibant is eliminated from the body), an oedema
episode could develop 6–8 hours after the surgery if BK remains high [8]. Other authors do not
support its use as short-term prophylaxis due to its short half-life [64].
4.12.6. Ecallantide (Kalbitor®, Shire HGT, Zug, Switzerland)
Ecallantide is a very potent, reversible and highly specific human plasma kallikrein inhibitor,
whose half-life is 2.0  0.5 hours [8]. Its effectiveness has been demonstrated in different
clinical trials [8, 14, 58, 65].
The United States Food and Drug Administration approved its use in December 2009 for the
treatment of acute AE episodes in patients aged 16 years and older with C1-INH-HAE. Later,
its use was extended to adolescents.
Acute allergic reactions, as well as anaphylaxis, have been reported [8].
It is administered subcutaneously at 30 mg (divided into 3 doses) and should be stored refriger-
ated [8]. One isolated case of STP with a low dose of ecallantide (10 mg) plus FFP, which did not
result in AE, was reported [66].
However, the short half-life of ecallantide (2.0  0.5 hours) could restrict its use as short-term
prophylaxis [8, 64]. It is necessary to carry out controlled studies or gain more experience in
order to recommend its use in this indication.
4.12.7. Recombinant human C1 inhibitor
Recombinant human C1-INH (rhC1INH) (Ruconest®/Rhucin®, Pharming Group NV, Leiden,
The Netherlands) is produced in transgenic female rabbits in which the human C1NH gene
has been inserted. The resulting rhC1INH is excreted in the rabbit milk, from which it is
obtained by purification. The active substance is also termed conestat alfa. rhC1INH is effec-
tive in the treatment of acute AE attacks. rhC1INH is a C1-INH replacement therapy but with
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the advantages of the absence of the potential risk of transmitting blood-borne human infec-
tions and its suitability for large-scale production. It has a similar inhibitory potency and high
structural analogy with phC1INH, although with a lower half-life (3 hours), due to differences
in glycosylation. rhC1INH can be kept at room temperature (2–25C). A 50 U/kg dose (maxi-
mum 4200 U) was approved by the EMA in October 2010 for the treatment of acute AE attacks
in > 18 years with C1-INH-HAE, although it has not yet been marketed in Spain. In 2016, its
approval was extended to adolescents.
FDA approved rhC1INH in 2014 for the treatment of acute AE attacks in adolescents and adult
patients with C1-INH-HAE. The approved dose is 50 U/kg with a maximum dose of 4200 U
administered intravenously.
A possible disadvantage of recombinant products is being potentially immunogenic and
having the risk of producing neutralizing antibodies and/or allergic reactions. However, data
on immunological safety are good, with no antibody production and no adverse immunolog-
ical effects observed, except for an anaphylactic reaction in one patient with undisclosed rabbit
allergy in a phase I clinical trial [8, 57].
rhC1INH is not recommended for short-term prophylactic management of C1-INH-HAE due
to its short half-life [64].
Two consensus for the management of C1-INH-HAE in children have been published in 22
2016 [50, 65, 66].
Caballero et al. published a consensus document in which the management of STP in female
patients was reviewed [67]. This information was updated later for HAE with and without
C1-inhibitor deficiency [68].
The unavailability of STP should not delay an urgent procedure [69]. C1-INH-HAE should not
be an obstacle for routine procedures [69].
In DOMFOP, it is advisable, provided that it is possible, to use regional anaesthesia to avoid
the trauma that supposes oropharyngeal intubation [8, 13, 70].
It is impossible to predict which patients will develop angioedema after a determined medical/
surgical procedure. Moreover, a single patient could present or not present AE after the same
procedure [70–72]. There are no controlled studies that assess STP efficacy; current available data
come from observational studies: The risk of perioperative AE without STP (not taking into
account dental procedures) is 6–31% [73]. There is no increased risk related to the procedure
location or surgical area size [73]. The prevalence of AE attacks after dental procedures
performed without STP varies from 5 to 37% of patients [71–73]. Farkas et al. observed that 40%
of the patients who had not performed STP developed AE post-procedures, when assessing all
the interventions as a whole [74]. Most times, AE is local, but distant AE has also been described
[72, 73]. AE can be triggered by minor procedures, such as local injection of a local anesthetic
[43], suture of a hand cut or an aesthetic injection of hyaluronic acid in the lips [72]. In some
patients, perioperative angioedema was the first manifestation of C1-INH-HAE [72].
The study of STP use in large patients’series has shown that STP with pdhC1INH or AAs reduced
the number of patients who present AE attacks after medical/surgical procedures [15, 71, 73].
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pdhC1INH reduced the AE risk more after invasive procedures than AAs and AAs more than
tranexamic acid [73]. It is important to emphasize that the AE risk after surgical/medical pro-
cedures is not completely avoided with STP [71, 73] and is independent of C1-INH-HAE severity
[15] and thus, at least one therapeutic dose of a specific treatment for acute AE attacks should be
available during and after the procedure [8, 74]. If the procedure involves the ENTarea, the patient
should be informed about the possibility to develop a laryngeal oedema, not only in the 12 hours
following the procedure but also later [72], and one should establish an action plan for the patient.
5. Conclusion: a proposal for STP algorithm
Based on the clinical experience of the Department of Allergology of the University Hospital
La Paz (Madrid) and the University General Hospital Nuestra Señora del Prado (Talavera de la
Reina), these algorithms have been updated and modified.
Most studies do not take into account the disease severity in order to plan STP and to study the
STP efficacy.
Jurado-Palomo et al. [15] calculated retrospectively the C1-INH-HAE severity by using the
Diagnostic, Therapeutic, and Management Algorithm for Hereditary Angioedema, from
Agostoni et al. [70] (Table 5). They studied the efficacy of STP with AAs and/or pdhC1INH in
patients with C1-INH-HAE and found that all the patients who suffered mild pharynx laryn-
geal AE curiously occurred in the group of patients with milder stages of C1-INH-HAE.
Curiously, these patients had not received long- or short-term AA prophylaxis nor pre-proce-
dural pdhC1INH [15].
Attack severity Score
Mild attacks (discomfort noticed, but no disruption of normal daily activities) 0.5 for each 24 hours
Moderate attacks (discomfort sufficient to reduce or affect normal daily activities) 1 for each 24 hours
Severe attacks (inability to work or perform daily activity) 2 for each 24 hours
Need for treatment:
- Emergency treatment: conservative, substitutive (C1-INH, FFP). 5 each
- Emergency treatment: invasive (intubation, tracheotomy). 25 each
- Long-term prophylaxis for more than 6 months. 25
- Long-term prophylaxis for 3–6 months. 12.5
Score Class Degree
>30 1 Severe
21–30 2 Moderate
11–20 3 Mild
1–10 4 Minimal
0 5 Asymptomatic
Table 5. Criteria for the evaluation of disease severity [70] (these parameters are determined over the period of 1 year.
The sum of the scores defines the severity of the disease for that year).
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We advise to classify procedures according to the risk of producing AE as minor, intermediate
and major risks.
If we classified dental procedures according to the surgical risk, the injection of local anaesthetic
would be of minor AE risk, but it has been identified to be able to precipitate an attack of AE [43].
In our series, even the placement of orthodontic appliances (lower risk according to our classifi-
cation) showed triggering of mild palate oedema in the months after the placement [15]. Thus, it
is important that patients have specific drugs, for the treatment of acute attacks, available.
We would recommend using danazol, stanozolol and tranexamic acid in minor risk manipu-
lations and not using tranexamic acid for those procedures of intermediate or major AE risk
and attenuated androgens if pdhC1INH is available.
Given this and in our experience, we would propose the following algorithms for the prophy-
laxis of DOMFOPs (Figure 5). To elaborate on this algorithm, three special mentions can be done:
Figure 5. Proposed algorithm for short-term prophylaxis in C1-INH-HAE according to the authors’ experience at Uni-
versity Hospital La Paz in Madrid and at University General Hospital Nuestra Señora del Prado in Talavera de la Reina.
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1. In an “intermediate” level of procedures, surgical risk is included, although it includes the
same prophylactic approach as greater surgical risk.
2. It is clearly specified that short-term prophylaxis to reduce AE risk after dental manipula-
tions should be performed even in patients with asymptomatic activity or minimal disease.
3. Stanozolol is included as a recommendation in lower risk manipulations, at the same level
as danazol or tranexamic acid.
Close coordination between different specialists is advisable to decide the attitude to follow
pre-procedurally. Treatment for acute attacks should be available in the operating room, in the
allergology department and even at patient's home.
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